How have FNCH shares performed in 2024?

Finch Therapeutics Group's stock was trading at $3.61 on January 1st, 2024. Since then, FNCH shares have decreased by 30.2% and is now trading at $2.52. View the best growth stocks for 2024 here .

Are investors shorting Finch Therapeutics Group?

Finch Therapeutics Group saw a decrease in short interest in March. As of March 31st, there was short interest totaling 9,200 shares, a decrease of 20.7% from the March 15th total of 11,600 shares. Based on an average daily volume of 17,700 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.7% of the company's stock are sold short. View Finch Therapeutics Group's Short Interest .

When is Finch Therapeutics Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our FNCH earnings forecast .

How were Finch Therapeutics Group's earnings last quarter?

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) announced its quarterly earnings data on Monday, March, 25th. The company reported ($1.89) earnings per share for the quarter.

When did Finch Therapeutics Group's stock split?

Finch Therapeutics Group's stock reverse split on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Finch Therapeutics Group IPO?

Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Finch Therapeutics Group?

Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:FNCH

Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

→ Forget Nvidia, buy this A.I. Stock Now (From InvestorPlace) (Ad)

Free FNCH Stock Alerts

Notice: Trading of Finch Therapeutics Group halted at 09:33 AM EST due to "LULD pause".

$2.52

-0.58 (-18.71%)

(As of 04/17/2024 ET)

Compare

Today's Range: $2.35
▼
$3.13
50-Day Range: $2.08
▼
$3.42
52-Week Range: $1.86
▼
$16.74

Volume: 127,984 shs
Average Volume: 28,524 shs
Market Capitalization: $4.05 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Finch Therapeutics Group alerts:

Finch Therapeutics Group MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
1.70% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.96
Based on 2 Articles This Week
Insider Trading: Selling Shares
$17,070 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.39 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Finch Therapeutics Group.

5.0

Short Interest

Percentage of Shares Shorted
1.70% of the float of Finch Therapeutics Group has been sold short.
Short Interest Ratio / Days to Cover
Finch Therapeutics Group has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Finch Therapeutics Group has recently decreased by 20.69%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Finch Therapeutics Group does not currently pay a dividend.
Dividend Growth
Finch Therapeutics Group does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FNCH.

2.8

News and Social Media Coverage

News Sentiment
Finch Therapeutics Group has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Finch Therapeutics Group this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for FNCH on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Finch Therapeutics Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Finch Therapeutics Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,070.00 in company stock.
Percentage Held by Insiders
44.90% of the stock of Finch Therapeutics Group is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 21.77% of the stock of Finch Therapeutics Group is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Finch Therapeutics Group is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Finch Therapeutics Group is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Finch Therapeutics Group has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

Forget Nvidia, buy this A.I. Stock Now

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

About Finch Therapeutics Group Stock (NASDAQ:FNCH)

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

FNCH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FNCH Stock News Headlines

March 31, 2024 | insidertrades.com

Jeffery A. Smisek Sells 6,642 Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Stock

April 14, 2024 | fool.com

Finch Therapeutics Group (NASDAQ: FNCH)

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

March 25, 2024 | investorplace.com

FNCH Stock Earnings: Finch Therapeutics Gr Reported Results for Q4 2023

March 7, 2024 | investing.com

Finch Therapeutics Group Inc (FNCH)

February 22, 2024 | benzinga.com

Finch Therapeutics Gr Stock (NASDAQ:FNCH), Short Interest Report

November 5, 2023 | morningstar.com

Finch Therapeutics Group Inc FNCH

August 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH)

April 17, 2024 | InvestorPlace (Ad)

Forget Nvidia, buy this A.I. Stock Now

June 9, 2023 | finanznachrichten.de

Finch Therapeutics Group, Inc.: Finch Announces Reverse Stock Split of Common Stock

May 13, 2023 | msn.com

HC Wainwright & Co. Reiterates Finch Therapeutics Group (FNCH) Buy Recommendation

May 12, 2023 | marketwatch.com

8-K: Finch Therapeutics Group, Inc.

May 10, 2023 | finanznachrichten.de

Finch Therapeutics Group, Inc.: Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

May 10, 2023 | finance.yahoo.com

Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

April 25, 2023 | finance.yahoo.com

Finch Therapeutics Announces Executive Leadership Transitions

April 22, 2023 | finanznachrichten.de

FINCH THERAPEUTICS GROUP INC

April 18, 2023 | finance.yahoo.com

Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement

April 4, 2023 | markets.businessinsider.com

Finch Therapeutics Group (FNCH) Gets a Buy from H.C. Wainwright

April 3, 2023 | finanznachrichten.de

Finch Therapeutics Group, Inc.: Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 25, 2023 | msn.com

Looking Into Finch Therapeutics Group's Return On Capital Employed

March 25, 2023 | finance.yahoo.com

Finch Therapeutics Group Full Year 2022 Earnings: Misses Expectations

March 23, 2023 | finance.yahoo.com

Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

January 24, 2023 | finance.yahoo.com

Microbiome startup cuts 95% of remaining staff in 3rd layoff in 9 months

January 24, 2023 | marketwatch.com

Finch Therapeutics Ending Phase 3 Study, Cutting Most of Workforce >FNCH

January 24, 2023 | finance.yahoo.com

Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets

November 11, 2022 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Kezar Life Sciences (KZR), RVL Pharmaceuticals (RVLP)

November 11, 2022 | finance.yahoo.com

Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

See More Headlines

Receive FNCH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Finch Therapeutics Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/25/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:FNCH
CUSIP: N/A
CIK: 1733257
Web: www.finchtherapeutics.com
Phone: 617-229-6499
Fax: N/A
Employees: 18
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($47.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-74,750,000.00
Net Margins: N/A
Pretax Margin: -73,098.12%
Return on Equity: -136.63%
Return on Assets: -57.40%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.33
Quick Ratio: 6.33

Sales & Book Value

Annual Sales: $107,000.00
Price / Sales: 37.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.25 per share
Price / Book: 0.18

Miscellaneous

Outstanding Shares: 1,606,000
Free Float: 885,000
Market Cap: $4.05 million
Optionable: No Data
Beta: 0.46

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Matthew P. Blischak J.D.
Chief Executive Officer
Mr. Lance Thibault CPA (Age 58)
Chief Financial Officer
Mr. James S. Sigler MBA (Age 63)
Executive Vice President of CMC

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

FNCH Stock Analysis - Frequently Asked Questions

How have FNCH shares performed in 2024?: Finch Therapeutics Group's stock was trading at $3.61 on January 1st, 2024. Since then, FNCH shares have decreased by 30.2% and is now trading at $2.52.
View the best growth stocks for 2024 here.
Are investors shorting Finch Therapeutics Group?: Finch Therapeutics Group saw a decrease in short interest in March. As of March 31st, there was short interest totaling 9,200 shares, a decrease of 20.7% from the March 15th total of 11,600 shares. Based on an average daily volume of 17,700 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.7% of the company's stock are sold short.
View Finch Therapeutics Group's Short Interest.
When is Finch Therapeutics Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FNCH earnings forecast.
How were Finch Therapeutics Group's earnings last quarter?: Finch Therapeutics Group, Inc. (NASDAQ:FNCH) announced its quarterly earnings data on Monday, March, 25th. The company reported ($1.89) earnings per share for the quarter.

When did Finch Therapeutics Group's stock split?: Finch Therapeutics Group's stock reverse split on Monday, June 12th 2023. The 1-30 reverse split was announced on Monday, June 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
When did Finch Therapeutics Group IPO?: Finch Therapeutics Group (FNCH) raised $101 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO.
How do I buy shares of Finch Therapeutics Group?: Shares of FNCH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FNCH) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Finch Therapeutics Group (FNCH) Stock Price, News & Analysis

Finch Therapeutics Group MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Finch Therapeutics Group Stock (NASDAQ:FNCH)

FNCH Stock Price History

FNCH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

FNCH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™